- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 19.02. | Perceive Pharma secures $15m to advance neuroprotective therapeutic development | ||
| 18.02. | SpringWorks Therapeutics selects Onco360 as pharmacy partner for Gomekli | ||
| 17.02. | US FDA approves Deciphera's Romvimza for TGCT treatment | ||
| 14.02. | Conduit and Charles River to evaluate AZD1656 in SLE model | ||
| 13.02. | ExpressionEdits and Boehringer Ingelheim partner to optimise gene therapies | ||
| 12.02. | FDA to review Regeneron's linvoseltamab BLA for multiple myeloma treatment | ||
| 11.02. | AdvanCell, Lilly partner on new targeted alpha therapies for cancer treatment | ||
| 10.02. | Norgine launches sodium thiosulfate injection in Germany | ||
| 07.02. | Essential and Clinigen expand JAPAC partnership to drive patient access | ||
| 06.02. | DEBRA Research and LEO Pharma partner for skin disease therapies | ||
| 05.02. | FDA clears Auron's AUTX-703 IND to treat haematological malignancies | ||
| 04.02. | BioNTech concludes acquisition of biotechnology company Biotheus | ||
| 03.02. | EMA's CHMP recommends approval of Bristol Myers Squibb's HCC treatment combo | ||
| 31.01. | Rad AI raises $60m to accelerate generative AI technology development | ||
| 30.01. | Scholar Rock submits application of SMA therapy to FDA | ||
| 29.01. | Atalanta Therapeutics secures $97m in Series B round to advance RNAi therapies | ||
| 28.01. | Manas AI launches to focus on cancer medicine discovery | ||
| 27.01. | EMA validates X4's mavorixafor application for WHIM syndrome treatment | ||
| 24.01. | FDA approves Amneal Pharmaceuticals' Alzheimer's and oncology treatments | ||
| 23.01. | Kamada to supply immune globulin products in Latin America | ||
| 22.01. | FDA grants fast track status to Nacuity's NPI-001 for retinitis pigmentosa | ||
| 21.01. | Health Canada authorises Roche's Vabysmo for certain eye conditions | ||
| 20.01. | Fermion and Simcere to partner on development of pain treatment drug | ||
| 17.01. | Micron Biomedical secures funds for needle-free vaccine development | ||
| 16.01. | FDA clears Axcynsis' AT03-65 IND for CLDN6-positive solid tumours |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .